DBV Technologies S.A. (NASDAQ:DBVT) Sees Large Decline in Short Interest

DBV Technologies S.A. (NASDAQ:DBVT) saw a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 366,700 shares, a decrease of 70.9% from the November 15th total of 1,260,000 shares. Currently, 1.8% of the shares of the stock are sold short. Based on an average trading volume of 141,300 shares, the short-interest ratio is currently 2.6 days.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. StockNews.com assumed coverage on DBV Technologies in a research note on Sunday. They issued a “hold” rating for the company. HC Wainwright raised their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a report on Tuesday.

DBV Technologies Stock Performance

Shares of DBV Technologies stock traded down $0.16 during trading hours on Wednesday, hitting $3.29. The company’s stock had a trading volume of 1,310,093 shares, compared to its average volume of 51,000. The stock has a market cap of $67.68 million, a price-to-earnings ratio of -0.75 and a beta of 0.64. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $10.70. The firm has a fifty day moving average of $3.45 and a 200-day moving average of $4.04.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.